U.S. Crackdown on Chinese Biotech Could Harm Patients
America's crackdown on Chinese biotech could lead to drug shortages and higher costs, impacting patients without delivering promised security benefits.
- Latest
- Trending
America's crackdown on Chinese biotech could lead to drug shortages and higher costs, impacting patients without delivering promised security benefits.
Hong Kong's Hang Seng index surged 2.4% as traders bet on China-exposed stocks ahead of mainland market reopening. Real estate ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.